share_log

Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

北極兔生物科技股票:分析師觀點深度剖析(4個評分)
Benzinga ·  08/14 10:00
Analysts' ratings for Caribou Biosciences (NASDAQ:CRBU) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
四位分析師提供的分析師對Caribou Biosciences(納斯達克股票代碼:CRBU)在上個季度的評級從看漲到看跌不等。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級,展示了過去30天內不斷變化的情緒,並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Caribou Biosciences, revealing an average target of $10.25, a high estimate of $14.00, and a low estimate of $9.00. A 26.79% drop is evident in the current average compared to the previous average price target of $14.00.
分析師已經爲Caribou Biosciences設定了12個月的目標股價,顯示平均目標股價爲10.25美元,最高估計爲14.00美元,低估值爲9.00美元。與之前的平均目標股價14.00美元相比,當前的平均價格下降了26.79%。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級:仔細觀察
The perception of Caribou Biosciences by financial experts is analyzed through recent analyst...
通過分析師最近的行動,分析...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論